case_images: PMC2779324_01
case_images: Clinical course of patient number 3.
case_images: jkms-20-947-g001.jpg
case_images: PMC2779324_01_jkms-20-947-g001.jpg
case_images: F1
case_images: A decrease in drainage was observed at an average of 3.1 days after the initiation of somatostatin, as the dose of somatostatin had increased enough to produce an effect (Fig. 1).
case_images: Clinical course of patient number 6.
case_images: jkms-20-947-g002.jpg
case_images: PMC2779324_01_jkms-20-947-g002.jpg
case_images: F2
case_images: In patient 6 and patient 9, a rebound phenomenon of chylothorax was noted upon the reduction of somatostatin therapy, but the rebound effusion responded promptly when the dose of somatostatin was boosted (Fig. 2).
case_images: PMC2779324_02
case_images: Clinical course of patient number 4.
case_images: jkms-20-947-g003.jpg
case_images: PMC2779324_02_jkms-20-947-g003.jpg
case_images: F3
case_images: In this patient, superior vena cava syndrome was considered a contributing factor for the prolonged chylous drainage, but the high dose somatostatin infusion was tolerated for 21 days without any apparent side effects (Fig. 3).
case_images: PMC2779324_03